55 results
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax … or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than
6-K
EX-99.1
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary … of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
, including the anticipated starting and ending dates of our anticipated clinical trials;
our assessment of the potential of our pharmaceutical product … consumption. A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland
F-3/A
SPRC
SciSparc Ltd
20 Nov 23
Shelf registration (foreign) (amended)
4:22pm
the anticipated starting and ending dates of our anticipated clinical trials;
our assessment of the potential of our pharmaceutical product candidates
F-3
gloysbp 58a
3 Nov 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.2
ovsj1mg
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-10.1
gpdecdm1v
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-1.1
97z ll1abp4hdmfu
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
15tgcctm07e
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
lrbritna9m77ts f0
10 Aug 23
Prospectus supplement
6:32am
6-K
EX-99.1
v5i6kb1l19p6 f3miy
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
6-K
EX-99.1
dx00q8
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.2
p5aurkrg
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
r2mdmveujtmho
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.3
5bhlfnn0wbc
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
F-3
4o3q0k2tjs
7 Jul 22
Shelf registration (foreign)
4:22pm
6-K
EX-99.3
ssov5vuzz3kg ma
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.1
p3yg7p3lb
24 May 22
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
8:31am